Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 3/20 | 0.33 |
| ▸ | GABRD | O14764 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.33 |
| ▸ | GABRE | P78334 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL1436676 | 0.93 | — | — | |
| Alanine SCHEMBL10814860 | 0.93 | SLC7A5 (0.38) | SLC7A5CA1CA2CYP3A4TSHR | |
| Alanine SCHEMBL5943276 | 0.93 | SLC7A5 (0.38) | SLC7A5CA1CA2CYP3A4TSHR | |
| Alanine SCHEMBL19326825 | 0.93 | SLC7A5 (0.38) | SLC7A5CA1CA2CYP3A4TSHR | |
| Alanine SCHEMBL7616260 | 0.93 | SLC7A5 (0.38) | SLC7A5CA1CA2CYP3A4TSHR | |
| Alanine SCHEMBL7532124 | 0.93 | CA1 (0.44) | SLC7A5CA1CA2CYP3A4TSHR | |
| Alanine SCHEMBL735033 | 0.93 | — | — | |
| Alanine SCHEMBL7614895 | 0.93 | SLC7A5 (0.38) | SLC7A5CA1CA2CYP3A4TSHR | |
| Alanine SCHEMBL4669777 | 0.93 | — | — | |
| Alanine SCHEMBL5200274 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133630-A1 | CHEMICALLY DISRUPTABLE MOLECULE SWITCH AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2024-06-27 | — | — | WO | disclosed |
| CN-110218246-A | ANP32 albumen maintains the application in influenza virus polymerase activity in host | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 2019-09-10 | — | — | CN | disclosed |
| WO-2013040540-A2 | BIOBASED COMPOSITIONS OF DIAMMONIUM SUCCINATE, MONOAMMONIUM SUCCINATE AND/OR SUCCINIC ACID AND DERIVATIVES THEREOF | BIOAMBER INTERNATIONAL S.A.R.L. (LU) | 2013-03-21 | — | — | WO | disclosed |
| US-20130072714-A1 | BIOBASED COMPOSITIONS OF DIAMMONIUM SUCCINATE, MONOAMMONIUM SUCCINATE AND/OR SUCCINIC ACID AND DERIVATIVES THEREOF | BioAmber International S.à.r.l. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-8114839-B2 | Protease resistant modified erythropoietin polypeptides | HANALL BIOPHARMA CO., LTD. (KR) | 2012-02-14 | — | — | US | disclosed |
| US-8105573-B2 | Protease resistant modified IFN beta polypeptides and their use in treating diseases | HANALL BIOPHARMA CO., LTD. (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8057787-B2 | Protease resistant modified interferon-beta polypeptides | HANALL BIOPHARMA CO., LTD. (KR) | 2011-11-15 | — | — | US | disclosed |
| US-8052964-B2 | Interferon-β mutants with increased anti-proliferative activity | HANALL BIOPHARMA CO., LTD. (KR) | 2011-11-08 | — | — | US | disclosed |
| US-7998469-B2 | Modified interferon beta for use in treatment and prevention of autoimmune, nervous system, cell proliferative, liver, blood and infcetious disorders; directed protein design | HANALL BIOPHARMA CO., LTD. (KR) | 2011-08-16 | — | — | US | disclosed |
| US-20110142801-A1 | PROTEASE RESISTANT MODIFIED INTERFERON-BETA POLYPEPTIDES AND THEIR USE IN TREATING DISEASES | HANALL BIOPHARMA CO., LTD. (KR) | 2011-06-16 | — | — | US | disclosed |
| US-20050202438-A1 | Rational directed protein evolution using two-dimensional rational mutagenesis scanning | HANALL PHARMACEUTICAL CO., LTD. (KR) | 2005-09-15 | — | — | US | disclosed |
| EP-1539960-A2 | RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES | Nautilus Biotech (FR) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539950-A1 | RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS SCANNING | Nautilus Biotech (FR) | 2005-06-15 | — | — | EP | disclosed |
| US-20040132977-A1 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules | HANALL BIOPHARMA CO., LTD. (KR) | 2004-07-08 | — | — | US | disclosed |
| WO-2004022747-A1 | RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS SCANNING | NAUTILUS BIOTECH (FR) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022593-A2 | RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES | NAUTILUS BIOTECH (FR) | 2004-03-18 | — | — | WO | disclosed |
| EP-0669980-B1 | METHOD OF CONTROLLING POLYPEPTIDE PRODUCTION IN BACTERIA | GENENTECH INC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-0669980-A1 | METHOD OF CONTROLLING POLYPEPTIDE PRODUCTION IN BACTERIA | GENENTECH, INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012636-A1 | METHOD OF CONTROLLING POLYPEPTIDE PRODUCTION IN BACTERIA | GENENTECH, INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5304472-A | Cells encoding a PstS variant under the transcriptional control of the wild-type E. coli pstS gene promotor to yield alkaline phosphatase | GENENTECH, INC. (US) | 1994-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072714-A1 | BIOBASED COMPOSITIONS OF DIAMMONIUM SUCCINATE, MONOAMMONIUM SUCCINATE AND/OR SUCCINIC ACID AND DERIVATIVES THEREOF | SDHA, SDHB, ADSL | SLC7A5 1377/4885CA1 186/4885CA2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.